Previous 10 | Next 10 |
Patient enrollment and site activation now underway Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and inn...
– Company on track to commence enrollment and dosing of Phase 2 study of Trappsol ® Cyclo™ for the treatment of Alzheimer’s disease before year end – Ongoing advancement of global pivotal study (TransportNPC™) evaluating Trappsol &...
Summary Treatments such as Aricept and likely simufilam that inhibit the formation of the nitro-oxidant peroxynitrite and speed its decomposition stabilize Alzheimer's disease for about a year. Treatments (blarcamesine, Trappsol Cyclo, panax ginseng) that inhibit the formation of ...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...
Cyclo Therapeutics press release ( NASDAQ: CYTH ): Q2 GAAP EPS of -$0.41 beats by $0.12 . Revenue of $0.54M (+125.0% Y/Y) misses by $0.08M . For further details see: Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M ...
– On track to commence Phase 2 study of Trappsol ® Cyclo™ for the treatment of Alzheimer’s Disease before year end – Continued execution on advancement of lead development program evaluating Trappsol ® Cyclo™ for Niemann-Pic...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...
INmune Bio and Alector are seeking to treat Alzheimer's disease by decreasing neuroinflammation while maintaining a healthy immune response. However, neither company's drug candidate appears to address the oxidative stress that precedes neuroinflammation. Anti-inflammatory drug ca...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Cyclo Therapeutics Inc. Website:
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while ...